Release issued 13th April 2004

April 13, 2004--Waltham, Mass.--Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the drug-treated diabetic retinopathy population will quadruple by 2012.

"The availability of effective surgical treatments coupled with the near total lack of effective pharmacotherapy for diabetic retinopathy has kept drug-treated rates--and thus pharmaceutical sales for this disease--exceedingly low," said Kat Neumeyer, analyst at Decision Resources. "However, the launch of novel drug therapies will prompt dramatic increases in the drug-treated population, which will nearly quadruple in the major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom)."

According to the new Pharmacor study entitled Diabetic Retinopathy, launches of novel drug therapies such as corticosteroid implants, oral PKCß inhibitors, somatostatin analogues, and VEGF antagonists will fuel the meteoric rise of retinopathy sales from just under $45 million in 2002 to nearly $700 million in 2012.

About Diabetic Retinopathy: Diabetic retinopathy affects an estimated 5.6 million diagnosed diabetics and is the leading cause of new blindness among adults aged 20-74. The launches of novel drug therapies for diabetic retinopathy--an indication currently managed only with surgical treatments--would revolutionize treatment and dramatically expand the diabetic retinopathy market.

About Pharmacor from Decision Resources: Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources: Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

www.decisionresources.com

###

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread